Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELIRI versus FOLFIRI for first-line treatment of colorectal cancer with inoperable liver metastases
ISRCTN19912492Phase 2Completed
- Sponsor
- Ministry of Higher Education, Science and Technology
- Start
- Jan 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, capecitabine, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Ministry of Higher Education, Science and Technology. Primary endpoints: Response rate and Rate of radical surgical resection. Started Jan 2004; status: completed.
02
Drugs
irinotecancapecitabinefluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN19912492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19912492.